Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 34, 2020 - Issue 6
243
Views
2
CrossRef citations to date
0
Altmetric
Research Articles

Silychristin derivatives conjugated with coniferylalcohols from silymarin and their pancreatic α-amylase inhibitory activity

ORCID Icon, , &
Pages 759-765 | Received 20 May 2018, Accepted 07 Jul 2018, Published online: 16 Nov 2018

References

  • Amniattalab A, Malekinejad H, Rezabakhsh A, Rokhsartalab-Azar S, Alizade-Fanalou S. 2016. Silymarin: A novel natural agent to restore defective pancreatic β cells in streptozotocin (STZ)-induced diabetic rats. Iran J Pharm Res. 15(3):493–500.
  • Borah A, Paul R, Choudhury S, Choudhury A, Bhuyan B, Das Talukdar A, Dutta Choudhury M, Mohanakumar KP. 2013. Neuroprotective potential of silymarin against CNS disorders: Insight into the pathways and molecular mechanisms of action. CNS Neurosci Ther. 19(11):847–853.
  • Cheng X-R, Jie R, Wang C-H, Guan B, Jin H-Z, Zhang W-D. 2013. Chemical constituents from Inula wissmanniana. Chem Nat Compd. 49(5):815–818.
  • Choudhary MI, Begum A, Abbaskhan A, Musharraf SG, Ejaz A. 2008. Two new antioxidant phenylpropanoids from lindelofia stylosa. Chem Biodivers. 5(12):2676–2683.
  • Csupor D, Csorba A, Hohmann J. 2016. Recent advances in the analysis of flavonolignans of Silybum marianum. J Pharm Biomed Anal. 130:301–317.
  • Esmaeil N, Anaraki SB, Gharagozloo M, Moayedi B. 2017. Silymarin impacts on immune system as an immunomodulator: One key for many locks. Int Immunopharmacol. 50:194–201.
  • Federico A, Dallio M, Loguercio C. 2017. Silymarin/Silybin and chronic liver disease: A marriage of many years. Molecules. 22(2):191.
  • Governa P, Baini G, Borgonetti V, Cettolin G, Giachetti D, Magnano A, Miraldi E, Biagi M. 2018. Phytotherapy in the management of diabetes: A review. Molecules. 23(1):105.
  • Hara Y, Honda M. 1990. The inhibition of α-Amylase by tea polyphenols. Agric Biol Chem. 54(8):1939–1945.
  • Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, Raza M. 2006. The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res. 20(12):1036–1039.
  • Kato E, Iwano N, Yamada A, Kawabata J. 2011. Synthesis and α-amylase inhibitory activity of glucose-deoxynojirimycin conjugates. Tetrahedron. 67(40):7692–7702.
  • Kazazis CE, Evangelopoulos AA, Kollas A, Vallianou NG. 2014. The therapeutic potential of milk thistle in diabetes. Rev Diabet Stud. 11(2):167–174.
  • Kren V, Walterova D. 2005. Silybin and silymarin-new effects and applications. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 149(1):29–41.
  • Ozdal T, Capanoglu E, Altay F. 2013. A review on protein–phenolic interactions and associated changes. Food Res Int. 51(2):954–970.
  • Lo Piparo E, Scheib H, Frei N, Williamson G, Grigorov M, Chou CJ. 2008. Flavonoids for controlling starch digestion: Structural requirements for inhibiting human α-Amylase. J Med Chem. 51(12):3555–3561.
  • Qin NB, Jia CC, Xu J, Li Dh, Xu FX, Bai J, Li ZL, Hua HM. 2017. New amides from seeds of Silybum marianum with potential antioxidant and antidiabetic activities. Fitoterapia. 119:83–89.
  • Rainone F. 2005. Milk thistle. Am Fam Physician. 72(7):1285–1288.
  • Razavi BM, Karimi G. 2016. Protective effect of silymarin against chemical-induced cardiotoxicity. Iran J Basic Med Sci. 19(9):916–923.
  • Sales PM, Souza PM, Simeoni LA, Silveira D. 2012. α-Amylase inhibitors: a review of raw material and isolated compounds from plant source. J Pharm Pharm Sci. 15(1):141–183.
  • Shahbazi F, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M. 2012. Potential renoprotective effects of Silymarin against nephrotoxic drugs: A review of literature. J Pharm Pharm Sci. 15(1):112–123.
  • Soto C, Pérez J, García V, Uría E, Vadillo M, Raya L. 2010. Effect of silymarin on kidneys of rats suffering from alloxan-induced diabetes mellitus. Phytomedicine. 17(14):1090–1094.
  • Soto C, Raya L, Juárez J, Pérez J, González I. 2014a. Effect of Silymarin in Pdx-1 expression and the proliferation of pancreatic β-cells in a pancreatectomy model. Phytomedicine. 21(3):233–239.
  • Soto C, Raya L, Pérez J, González I, Pérez S. 2014b. Silymarin Induces Expression of Pancreatic Nkx6.1 transcription factor and β-Cells Neogenesis in a pancreatectomy model. Molecules. 19(4):4654–4668.
  • Stolf AM, Cardoso CC, Acco A. 2017. Effects of Silymarin on diabetes mellitus complications: A review. Phytother Res. 31(3):366–374.
  • Voroneanu L, Nistor I, Dumea R, Apetrii M, Covic A. 2016. Silymarin in type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. J Diabetes Res. 2016:1–10.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.